JazzPharma y Roche Iniciarán una Fase III Combinatoria de Mantenimiento ... Que Concluirá el 1 de Marzo 2025 . A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in SCLC .

 

Lurbinectedin / Atezolizumab Small Cell Lung Cancer . PharmaMar Presentará un Abstract en el Congreso de la Sociedad de Inmunoterapia del Cáncer con los Primeros Datos del Ensayo Clínico de Fase I-II en Segunda Línea de la Combinación de Dichos Fármacos . El Ensayo Concluirá en 2022 .

Virilogos Ingleses , Egipcios , Suecos , Chinos ... Buscan Tratamiento Contra el COVID19 ... Bajo el Mar : Polisacáridos Sulfatados Marinos Como Agentes Antivirales Prometedores : Un Informe Completo y un Estudio de Modelado Centrado en el SARS CoV-2

Link : Promising COVID Treatments Could be Growing Under The Sea – Here’s How to Find Them .

More than 18 months into the pandemic, we’re still hunting for effective antiviral treatments for COVID – medicines that target the coronavirus itself and stop it from developing in the body.

So far we have only a handful of options. Remdesivir has been authorised for use, but the latest research shows it doesn’t improve outcomes for COVID patients, and so the World Health Organization has recommended it not be used. A new alternative, molnupiravir, will soon be available, but demand will be high. It could also be very expensive for some patients.

So if we need alternative antivirals, where will we find them? Possibly in nature. It’s an outstanding hub for valuable natural compounds, and provided us with one of the most important scientific discoveries in history: penicillin, the first naturally occurring antibiotic to be used therapeutically. Thanks to this drug, various diseases caused by bacteria are no longer life threatening.

There’s a very good chance that researchers could discover a highly effective antiviral agent in nature too, if they were able to test all of the substances within the natural environment. This, however, would be an enormous task. So we need to find shortcuts – which is something I and my colleagues have been working on.

Finding Medicines Under The Waves .

The marine environment in particular is a treasure trove for potential new medicines. Many products derived from marine organisms have been approved by the US Food and Drug Administration for medical use, for example, and many others are currently in different stages of clinical trials. However, the sea and its natural products are still under-investigated as far as medicines are concerned.

One set of substances that are particularly interesting are marine sulphated polysaccharides, or MSPs. These are a type of carbohydrate that contain sulphur, and are mainly found in the cell walls of marine algae or seaweeds. They’re also less commonly found in some fish skins and in mangrove plants.

They’re significant because they’ve shown that they can inhibit many disease-causing viruses, such as herpes simplex virus, HIV, chikungunya virus, cytomegalovirus, influenza and hepatitis virus.Promising COVID treatments could be growing under the sea – here’s how to find them

But even if we know MSPs in general are worth investigating, discovering which ones specifically are effective against SARS-CoV-2, the virus that causes COVID, would be very time and resource-consuming using traditional laboratory testing.

Simulating Interactions .

To get around this, my colleagues and I used computer-assisted methods to predict how MSPs would behave with the coronavirus, and so filter out those unlikely to work against it. Many drugs currently on the market were developed with this kind of assistance, including the flu treatment zanamivir and the HIV drugs nelfinavir and saquinavir.

First, we looked at past research, focusing on papers that mentioned MSPs having an effect against different viruses. We looked at around 80 papers, spanning 25 years, and came up with a shortlist of 45 substances that might potentially have an antiviral effect and so be worth investigating further.

These shortlisted MSPs came from various marine sources, including different types of algae, microalgae, sea cucumbers and squid cartilage.

...

EXPANSION : Gobierno de los Estados Unidos de América Ha Puesta Ya Encima de la Mesa 2200 Millones $ Para Adquirir la Píldora Oral , Mollnupiravir , de Merck .

 

EEUU Podría Aprobar el Tratamiento Oral COVID19 de MERCK en 20 DIAS . Estados Unidos Adquiere 1,4 Millones de Dosis Adicionales de Molnupiravir por 1.000 Millones de Dólares .

 

Este Medicamento Antiviral de Merck Sharp&Dohme y Ridgeback está Orientado al Tratamiento de los Casos de COVID19 de Leve a Moderado. 

Molnupiravir se Administra Mediante Vía Oral y Tiene Como Grupo Diana la Población Adulta .

Los Tratamientos contra el Covid-19 se diversifican.

 Estados Unidos ha adquirido 1,4 millones de dosis adicionales de molnupiravir por valor de 1.100 millones de dólares, según han informado Merck Sharp&Dohme y Ridgeback en un comunicado. Si se autoriza, este tratamiento estará entre las vacunas y medicamentos disponibles para combatir el Covid-19.

Este medicamento antiviral, producido y comercializado por estas dos compañías, está orientado al tratamiento de los casos de coronavirus de leve a moderado. Molnupiravir se administra mediante vía oral y tiene como grupo diana la población adulta.

 Con esta opción ejercida, el Gobierno de Estados Unidos ha adquirido un total de 3,1 millones de dosis de molnupiravir por valor de 2.200 millones de dólares. La administración estadounidense también tiene la capacidad de comprar más de dos millones de dosis adicionales mediante otras opciones que quedan en el contrato.

“Nos honra que el Gobierno de Estados Unidos nos haya elegido para comprar más de tres millones de dosis de molnupiravir; en Merck nos estamos moviendo con urgencia y rigor para llevar este tratamiento a los pacientes” ha explicado Frank Clyburn, presidente de Salud Humana de Merck MSD.

Las Ventas Netas de Zepzelca en el 3T21 Se Vieron Afectadas Favorablemente Por Aproximadamente $ 10 Millones , en Relación con una Reducción en la Tasa de Acumulación de Retornos, Debido a Retornos Reales Inferiores a los Estimados . Excluyendo este Impacto, las Ventas Netas en el 3T21 Aumentaron un 10% en Comparación con el 2T21 .